To access this element change to forms mode OFF
Grant Award View - GA30223
Translating cystic fibrosis gene-addition therapy for use in human...
GA ID:
GA30223
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2022
Value (AUD):
$861,345.40
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Translating cystic fibrosis gene-addition therapy for use in human lungs: Demonstrating efficacy, safety and scalability
Purpose:
Expensive drugs like Kalydeco can improve cystic fibrosis (CF) lung health, but only in some patients. Airway gene-addition therapy could treat any patient. Our successful airway gene therapy method could not be tested in CF lungs until our recent development of rats with CF. This project will precisely-target our gene therapy to lung regions, assess the effectiveness and safety with techniques including our revolutionary X-ray methods, and test its potential in the human-size lungs of sheep
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1160011
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Adelaide
Recipient ABN:
61 249 878 937
Grant Recipient Location
Suburb:
Adelaide
Town/City:
Adelaide
Postcode:
5000
State/Territory:
SA
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC, SA
Postcode:
Multiple
Country:
AUSTRALIA